SCHEMBL2941508

SCHEMBL2941508

CCCCCOc1ccc(C(CC(=O)O)c2ccccc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 1/20 0.65
MMP8 P22894 1/20 0.65
MMP13 P45452 1/20 0.65
FFAR1 O14842 1/20 0.64
SMN1; SMN2 Q16637 2/20 0.63
LMNA P02545 1/20 0.58
POLB P06746 2/20 0.57
TDP1 Q9NUW8 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
GPR88 Q9GZN0 2/20 0.57
LTA4H P09960 1/20 0.55
TP53 P04637 1/20 0.55
TSHR P16473 1/20 0.55
S1PR1 P21453 1/20 0.54
S1PR3 Q99500 1/20 0.54
PLA2G4B P0C869 1/20 0.54
ALDH1A1 P00352 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2939695 0.99 MMP9 (0.67) MMP9MMP8MMP13FFAR1SMN1; SMN2
SCHEMBL2949131 0.99 MMP9 (0.67) MMP9MMP8MMP13FFAR1SMN1; SMN2
SCHEMBL2948148 0.97 FFAR1 (0.68) MMP9MMP8MMP13FFAR1SMN1; SMN2
SCHEMBL9474072 0.95 MMP9 (0.70) MMP9MMP8MMP13FFAR1SMN1; SMN2
SCHEMBL2947981 0.91 SMN1; SMN2 (0.74) MMP9MMP8MMP13FFAR1SMN1; SMN2
SCHEMBL2949664 0.87 CYSLTR2 (0.61) MMP9MMP8MMP13SMN1; SMN2LMNA
SCHEMBL13236679 0.86 SMN1; SMN2 (0.53) MMP9MMP8MMP13FFAR1SMN1; SMN2
SCHEMBL2946000 0.85 FFAR1 (0.60) MMP9MMP8MMP13FFAR1SMN1; SMN2
SCHEMBL13236687 0.85 LMNA (0.55) MMP9MMP8MMP13SMN1; SMN2LMNA
SCHEMBL13236684 0.85 LMNA (0.55) MMP9MMP8MMP13SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750048-B2 GPR40 agonists JANSSEN PHARMACEUTICA NV (BE) 2010-07-06 US claimed
US-20080176912-A1 GPR40 AGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-24 US claimed
US-7750048-B2 GPR40 agonists JANSSEN PHARMACEUTICA NV (BE) 2010-07-06 US disclosed
US-7750048-B2 GPR40 agonists JANSSEN PHARMACEUTICA NV (BE) 2010-07-06 US disclosed
US-7750048-B2 GPR40 agonists JANSSEN PHARMACEUTICA NV (BE) 2010-07-06 US disclosed
US-20080176912-A1 GPR40 AGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-24 US disclosed
US-20080176912-A1 GPR40 AGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-24 US disclosed
US-20080176912-A1 GPR40 AGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176912-A1 GPR40 AGONISTS GPR119, GPR65, GPR55 MMP9 4828/4885MMP8 4442/4885MMP13 4524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.